Volume 28, Number 3—March 2022
Research
Overseas Treatment of Latent Tuberculosis Infection in US–Bound Immigrants
Figure 2

Figure 2. Flowchart of US immigrant visa applicants who consented to participate, initiated treatment, and completed treatment along the latent TB infection cascade of care in the Preventing Tuberculosis Overseas Pilot Study, Vietnam, 2018–2019. Participants who completed ≥8 doses of 3HP by DOT in Vietnam were given the option of taking the remaining ≤4 doses by SAT after arrival in the United States. DOT, directly observed therapy; IGRA, interferon-γ release assay; LTBI, latent tuberculosis infection; SAT, self-administered therapy; TB, tuberculosis; 3HP, 3-month regimen of isoniazid and rifapentine.
Page created: December 13, 2021
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.